Menarini Stemline Symposium

Beyond monotherapy: Unlocking synergy in
myelofibrosis treatment

Friday, October 16th 2026
14:15–15:30 CEST
Hall B

Session description (optional, max 200 words): Join our esteemed faculty as they discuss a new era in myelofibrosis treatment during this live, engaging, 75-minute symposium. The session will examine the need to move beyond spleen and symptoms towards disease modification, review the emerging landscape of investigational JAKi-based combinations, and explore the biological rationale for XPO1 inhibition in combination with JAK inhibition as a novel treatment strategy in myelofibrosis.

Abbreviations: JAK, Janus kinase; JAKi, Janus kinase inhibitor; XPO1, exportin-1.

Mohamad Mohty

France

Moderator

Bio

Mohamad Mohty

Dr Mohamad Mohty is a full Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint Antoine Hospital and Sorbonne University in Paris, France. He obtained his medical degree from the University of Montpellier, France, and PhD from the University of Marseille, France. He is also head of a translational research team ( Inserm ) at the Saint Antoine Research Centre in Paris.

Dr Mohty is the past president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of the EBMT . He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and board member of the EBMT and the Intergroupe Francophone du Myelome (IFM).

In addition to publishing more than 900 peer reviewed articles in the field of stem cell transplantation, leukemia, and myeloma, Dr Mohty also serves as Editor in Chief of the journals Bone Marrow Transplantation and Clinical Hematology International . He also serves as an editor, board member, and/or reviewer across numerous other reputable journals

Alessandro Vannucchi

Italy

Bio

Alessandro Vannucchi

Prof. Alessandro Vannucchi

Prof. Alessandro Vannucchi is Full Professor of Haematology at the University of Florence, where he founded the Centre of Research and Innovation in Myeloproliferative Neoplasms (CRIMM). He currently serves as Director of the Haematology Department and Director of the Oncology Department at the University of Florence and Azienda Ospedaliera Universitaria Careggi. He also holds several academic leadership positions, including Director of the Postgraduate School in Haematology.

Prof. Vannucchi is Chair of European LeukemiaNet Package 9 and of the GIMEMA Foundation Working Party on Myeloproliferative Neoplasms (MPNs), and Principal Investigator of the Italian MyNERVA research alliance focused on MPNs and related myeloid disorders. He is a member of the board of the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) and the European Haematology Association Specialised Working Group on Myeloproliferative Neoplasms. He currently serves as President of the Italian Society of Experimental Haematology.

His principal research interests include myeloproliferative neoplasms and the molecular genetics of myeloid neoplasms, including leukemia. He has served as Principal Investigator in more than 70 clinical trials and has authored or co-authored more than 720 peer-reviewed publications, predominantly in the field of MPNs. He is a frequent speaker at national and international scientific meetings.

Prof. Vannucchi’s scientific contributions have received international recognition. In 2024, he received the Award for “Scientific Achievements in MPN” at the New York Annual MPN Meeting. Since 2017, he has been recognised among the Web of Science “Highly Cited Researchers” in Clinical Medicine, as a highly ranked scholar by ScholarGPS, and among the “Top 100 Italian Scientists.” In 2023, he was appointed Commander of the Order of Merit of the Italian Republic by President Sergio Mattarella in recognition of his scientific achievements.

Lina Benajiba

France

Bio

Lina Benajiba

Pr Lina Benajiba

ATIP-Avenir & ERC-Stg team leader

Université Paris Cité

Paris Saint-Louis Leukemia Institute

INSERM U1342, Saint-Louis Research Institute – Paris

Clinical Investigations Center, Saint-Louis Hospital, APHP – Paris

As part of the French national MD-PhD program, Lina conducted her PhD training (2014-2018) at the Dana Farber Cancer Institute in Boston, focusing on the identification and characterization of new therapeutic targets in acute myeloid leukemia (AML). Lina also trained as a physician and obtained her MD from the Paris Cité University with a specialization in both hematology and pharmacology in 2019. Since 2023, Lina leads a research team developing large-scale descriptive and functional translational approaches to better understand myeloid leukemogenesis and decipher innovative therapeutic strategies, with a particular focus on the niche-leukemic crosstalk and environment driven oncogenic signals. Lina’s team obtained an ERC starting research grant in 2024. Lina’s clinical efforts are currently focused on early drug development in myeloproliferative neoplasms and AML. Lina is a full professor at Paris Cité University and leads several teaching programs in pharmacology and onco-hematology.

Claire Harrison

United Kingdom

Bio

Claire Harrison

Professor Claire Harrison graduated from Oxford Univeristy Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy medical director.

The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. In addition to the PT-1 trial, MAJIC, COMFORT-II, JAKARTA-2 and PERSIST-1 where she is currently the global chief or co-chief investigator, she has a leadership role in over 20 clinical trials. This work has led to the approval of new therapies such a ruxolitinib, fedratinib and pacritinib. Translational research has been supported with a grant income of over £10M in the past 5 years. JAK2 exon 12 mutations, genetic suseptibility and the impact of the order of mutations in MPN. In the past 10 years she has published widely (>250 academic articles).

In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.

The clinical MPN service at GSTT is large, comprehensive and is internationally recognised as a centre of excellence.

Agenda
14:15–14:20	Introduction Mohamad Mohty, France
14:20–14:35	Going beyond spleen and symptoms: What should we look at? Alessandro Vannucchi, Italy
14:35–14:55	Combination therapy in JAKi-naïve patients: Where are we? Lina Benajiba, France
14:55–15:15	XPO1 inhibition: Biological rationale and clinical data Claire Harrison, United Kingdom
15:15–15:30	Conclusion All faculty (moderated by Mohamad Mohty)

Beyond monotherapy: Unlocking synergy in
myelofibrosis treatment

Moderator

The 9th Annual Meeting of the
International Academy for
Clinical Hematology (IACH)

Meeting venue

Meeting organizers

IACH Meeting

Menarini Stemline Symposium

Beyond monotherapy: Unlocking synergy in myelofibrosis treatment

Moderator

The 9th Annual Meeting of the International Academy for Clinical Hematology (IACH)

Meeting venue

Meeting organizers

IACH Meeting

Beyond monotherapy: Unlocking synergy in
myelofibrosis treatment

The 9th Annual Meeting of the
International Academy for
Clinical Hematology (IACH)